Addimmune's CEO on how the company is trying to harness modifying miRNAs to create a functional cure for HIV

blonca9
Jan 18, 2024
1 min read

Jeff Galvin explains how previous attempts at modifying CCR5 in T-cells have taught his company to more precisely target HIV and from additional angles.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Addimmune's CEO on how the company is trying to harness modifying miRNAs to create a functional cure for HIV

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight